A Detailed Analysis of the Rat Model Market Based on Genetic Advancements and Increasing Preclinical Research Demands
Report ID: PMRREP33949
Number of Pages: 211
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: January-2024
The global Rat Model market is forecast to expand at a CAGR of 6.8% and thereby increase from a value of US$1.3 Bn in 2023, to US$2.1 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
Rat Model Market Size (2023E) |
US$1.3 Bn |
|
Projected Market Value (2030F) |
US$2.1 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
6.8% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
7.5% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
Rat models, also called laboratory rats, are widely used in science to investigate a wide range of topics, including physiology, genetics, behavior, and illness. Rats are useful models for experiments because of their close biological resemblance to humans. Their application in research spans from the production of drugs and toxicological analyses to the comprehension of intricate biological mechanisms. These models help researchers learn more about human health and facilitate the exploration and creation of novel cures. Rats are now favored in pharmacological and biomedical research because of their very short reproductive cycles and simplicity of handling.
The growing need for preclinical investigations in pharmaceutical development is driving significant growth in the rat model industry. The growing incidence of chronic illnesses, the demand for efficient medication development, and the developments in genetic engineering methods are the main factors driving the industry. Furthermore, the ability of rat models to replicate a variety of human circumstances increases their research value and supports the general growth of the rat model business.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionAdvancements in Genetic Engineering Techniques
The market for rat models has advanced tremendously due to the rapid breakthroughs in genetic engineering. Preclinical investigations are now more accurate and pertinent because of the capacity of researchers to edit the rat genome precisely to develop models that closely resemble human diseases. The area has undergone a revolution with the development of technologies such as CRISPR-Cas9, which have made it possible to introduce particular mutations or perform targeted changes such as gene knockouts in the rat genome. Due to these capabilities, rat models can now be used to research a greater variety of diseases, such as cancer, neurological problems, and cardiovascular ailments. The need for rat models is anticipated to endure and increase, propelling the market as a whole as long as researchers keep improving and developing genetic engineering techniques.
In addition, the need for rat models in preclinical research is mostly driven by the rising incidence of chronic diseases worldwide. The increasing prevalence of diseases such as diabetes, cardiovascular disorders, and neurodegenerative disorders has led to a growing demand for dependable animal models capable of faithfully capturing the intricate molecular pathways underlying these illnesses. Rat models are useful for researching the underlying causes of various illnesses and assessing possible treatment strategies because of their physiological and genetic resemblance to humans. Rat models are being used more and more by pharmaceutical and biotechnology companies to speed up the drug development process due to the rising burden of chronic diseases, which is driving the growth of the rat model market.
Challenges in Translating Findings to Human Relevance
The difficulty of extrapolating research results from rat studies to human clinical outcomes is a major barrier to the rat model industry. Although rats and humans share many physiological traits, some fundamental distinctions may make it difficult to extrapolate findings directly. This restriction affects the overall translational relevance of preclinical studies by making it more difficult to predict the safety and efficacy of therapeutic interventions in humans with any degree of accuracy based only on data from rat models.
Ethical and Regulatory Considerations
Rat model market participants encounter significant obstacles in the form of ethical and legal issues related to animal research. Stricter rules are required due to increased knowledge and scrutiny of the moral treatment of laboratory animals, particularly rats. For researchers and producers, striking a balance between the need for scientific developments and ethical considerations is a difficult task. The rat model market navigates a complicated landscape in which ethical difficulties in animal experiments must be addressed and adapted. This includes stricter legal frameworks, public concerns, and developing norms of behavior.
Expansion in Personalized Medicine Research
The rat model industry has a lot of potential because of its contribution to customized medicine research. Researchers may now generate rat models that more accurately reflect the genetic diversity present in human populations because of developments in genomic technologies. This makes it possible to conduct more accurate and customized research into each patient's unique response to therapy, which results in the creation of unique treatment plans. Rat models that can capture the nuances of human genetic variations are in high demand as the area of personalized medicine continues to gain traction. This presents a profitable opportunity for both academics and producers.
Moreover, the market for rat models can profit from the expanding use and interest in regenerative medicine. Because of their capacity for tissue regeneration in some areas, rats are useful models for research on stem cell treatments and tissue engineering. Scientists can investigate new treatments for ailments like degenerative disorders, cardiac diseases, and spinal cord injuries because they can replicate human-like regenerative processes in rat models. The need for rat models in cutting-edge therapeutics is anticipated to increase as regenerative medicine progresses, providing a favorable environment for market expansion and diversification.
Which Type Are Expected to Benefit the Most from Revenue Generation?
"Genetic Homogeneity Driving Inbred Rat Model Dominance”
The type segment is divided into knockout, outbred, inbred, hybrid, immunodeficient, and conditioned. The inbred sector of rat models is the largest because of its genetic homogeneity, which guarantees reliable and consistent study results. The dominance of this segment is partly due to the fact that researchers prefer using inbred rats to explore behavioral features, medication reactions, and hereditary components in diseases. Because genetic homogeneity reduces variability, experimental results are more reliable. The fastest-growing market is knockout, which is being pushed by developments in genetic engineering technology. Targeted genetic changes are made possible by the growing use of knockout rat models by researchers to examine the activities and processes of genes. The rapid expansion of this category is driven by the precision provided by knockout models, which expedites research into understanding disease processes and generating targeted therapeutics.
What Technology Will Be Holding the Most Market Share?
“Microinjection Dominate Owing to Precision in Genetic Manipulation Driving Rat Model Technology Advancements”
The Technology segment is bifurcated into Nuclear Transferase, Microinjection, Embryonic Stem cells, and Others. Microinjection has become the most prominent sector in rat model technology due to its ability to introduce genetic material into rat embryos with pinpoint accuracy. Microinjection is a widely used technique for gene editing and the generation of transgenic models. It enables focused changes, which improves the accuracy and efficiency of genetic manipulation in rats. Researchers highly value microinjection because of its adaptability and relevance to a wide range of research goals, which has led to its market dominance. The fastest-growing market is nuclear transferase technology, which is being driven by improvements in cloning methods. This technique makes it possible to produce genetically identical rats, which supports research that needs rats with similar genetic backgrounds. The nuclear transferase segment of the rat model technology market is growing at a quick pace due to the growing interest in creating customized rat models for certain research goals.
Which Area of Applications Should Be Focused on the Most Regarding Sales?
“Advancing Cancer Research Through Rat Models' Versatility and Precision”
The Application segment is sub-segmented into Oncology, Neurology, Immunology, Toxicology, and Other. The rat model market is dominated by the oncology application segment, which is driven by the constant need for cancer research. Rat models provide an excellent platform for researching the onset, spread, and management of tumors. The oncology segment's dominance is fueled by the predominance of studies connected to cancer, which is driven by the growing global burden of cancer. The field of immunology is experiencing the fastest growth due to the growing emphasis on creating immunotherapies, autoimmune illnesses, and understanding immune responses. Rat models are essential for deciphering intricate immunological pathways, which helps explain why the immunology market segment is expanding at a faster pace.
Which End User is Dominant Regarding Sales?
“Pharmaceutical & Biotech Companies to Dominate Sales Owing to Emphasizing Drug Development Efficacy And Safety”
The End User segment is categorized into CROs, Academic and Research Institutes, and Pharmaceutical and biotechnology Companies. The rat model market is dominated by the Pharmaceutical and biotechnology Companies segment, which is propelled by substantial preclinical research for drug development. These businesses have contributed to the importance of the industry by primarily using rat models to evaluate drug efficacy, safety, and pharmacokinetics. Because more pharmaceutical and biotech businesses are outsourcing preclinical investigations, CROs are the segment with the quickest rate of growth. CROs expedite the growth of this market segment by providing specialized expertise, cost-effectiveness, and efficiency in conducting studies using rat models.
Why is North America Emerging as a Dominating Region?
“Pharmaceutical Innovation and Research Collaboration Driving Rat Model Market Growth”
The pharmaceutical and biotechnology industries, well-established research infrastructure, and a high incidence of chronic illnesses propel North America to the top of the rat model market. North America's supremacy is partly attributed to the region's strong emphasis on novel medication research and the presence of important market participants. Furthermore, partnerships between academic institutions and business entities bolster the need for rat models in preclinical research, strengthening the area's dominant position in the market.
What Opportunities Lie in East Asia for Manufacturers?
“Rapid Expansion in East Asia's Rat Model Market Fueled by Research Surges
East Asia is distinguished as the region experiencing the most rapid expansion, primarily due to a notable upswing in research and development endeavors, with China and Japan leading the way. The rapidly expanding rat model industry in East Asia is driven by advances in genetic engineering technologies as well as rising investment in the biotechnology, pharmaceutical, and life sciences sectors. The region's significance in the worldwide market for rat models is also attributed to the availability of skilled researchers and an increasing emphasis on translational research.
What do our Analysts Predict for the Future of Rat Model Market?
According to PMR, the rat model market is expected to increase steadily due to improved research techniques and a rise in applications. Demand will be further fueled by the growing use of cutting-edge genetic editing methods like CRISPR-Cas9, which will continue to improve the accuracy and productivity of creating rat models. Rat models that replicate individual genetic variants are expected to increase as personalized medicine gains popularity and provides important information for customized treatment approaches. Rat models are also essential tools in drug discovery due to the increasing global frequency of chronic diseases and the critical need for trustworthy preclinical models.
Additionally, it is anticipated that regional market expansion will be fueled by the internationalization of research projects and partnerships between academic institutions, pharmaceutical corporations, and contract research organizations. The market for rat models is expected to continue growing steadily for the foreseeable future despite persistent difficulties with ethical issues. These issues are being addressed, and guidelines for ethical animal research are being developed.
Supply-side Dynamics
The market's supply-side dynamics for rat models are defined by a strong ecosystem that is fueled by partnerships between specialist suppliers, academic institutions, and biotechnology businesses. By investing in cutting-edge genetic engineering methods and managing breeding facilities, biotechnology businesses play a crucial role in the development and commercialization of rat models. These businesses frequently form strategic alliances with educational institutions and research centers in order to take advantage of their scientific know-how and guarantee the production of superior rat models that satisfy the various demands of the scientific community. The supply chain is further strengthened by the existence of reputable vendors who specialize in raising, housing, and managing rat colonies, giving researchers access to a wide range of resources and services.
Furthermore, advances in cryopreservation technologies facilitate the effective distribution and storage of genetically modified rat models, making them more accessible to researchers globally. The growing usage of contract research organizations (CROs) that specialize in preclinical services, such as the use of rat models for drug development and discovery, is also advantageous to supply-side dynamics. By providing affordable and specialized expertise to meet the diverse research demands of pharmaceutical and biotechnology companies, these CROs aid in the growth of the market as a whole. Overall, the rat model market is active and responsive because of the cooperative efforts and specialized services provided by different supply chain participants, guaranteeing a consistent and varied supply of high-quality models to support ongoing research endeavors.
The rat model market is characterized by intense competition, with major firms strategically concentrating on R&D, partnerships, and creative solutions. Prominent biotechnology and pharmaceutical firms, such as Charles River Laboratories, Envigo, TransViragen, Inc., Biomere, and Cyagen Biosciences, control the market with their vast arrays of genetically engineered rat models. These businesses make large investments in cutting-edge genetic engineering methods, guaranteeing a wide variety of rat models for numerous research applications, such as immunology, neurology, and oncology. These major firms' market reach is increased, and their research capabilities are strengthened through collaborations with academic institutions and research organizations.
Apart from well-established firms, emerging enterprises that focus on specialized fields like customized rat models or particular disease models are also present in the market. These participants frequently make use of cutting-edge technologies, concentrate on meeting particular research demands, and provide researchers with creative answers. Furthermore, by offering thorough preclinical services utilizing rat models, contract research organizations (CROs) enhance the competitive environment. Continuous innovation is encouraged by the competitive environment, which propels the creation of new models, enhanced breeding methods, and effective supply chain solutions. The competitive landscape is dynamic as the need for rat models grows across various research domains. Companies are trying to set themselves apart through technological advancements, strategic collaborations, and a customer-centric approach to meet the changing needs of the research community.
New Product Launch
The Research Models & Services (RMS) business of Charles River Laboratories Japan, Inc. (Japan) was bought by The Jackson Laboratory (US) in October 2021, becoming a wholly-owned subsidiary of Charles River Laboratories Japan.
Market Impact: The Jackson Laboratory's acquisition of Charles River Laboratories Japan's Research Models & Services (RMS) division is anticipated to affect the rat model market by fortifying the company's global footprint and broadening its range of products. This could result in higher competition and more options in the research models and services industry.
(Source: The Jackson Laboratory)
Cognate BioServices, Inc. (US), a cell and gene therapy contract development and manufacturing organization (CDMO) providing all-inclusive cell therapy manufacturing solutions, was purchased by Charles River Laboratories International, Inc. (US) in March 2021. Charles River now has more extensive capabilities for cell and gene therapies on all main CDMO platforms due to the acquisition.
Market Impact: Charles River Laboratories made a calculated strategic move to expand its skills in the field of cell and gene therapy in March 2021 when it acquired Cognate BioServices. Charles River's position as a leading provider of all-inclusive manufacturing solutions is reinforced by this expansion, which also can impact the industry by delivering integrated services and advancing the field of cell and gene therapy research.
(Source: Charles River Laboratories)
In September 2021, Biocytogen (US) and Envigo (US) partnered to support the research applications of the triple immunodeficient B-NDG mouse. B-NDG mice are only available from Envigo in the US, Europe, and some APAC countries.
Market Impact: Access to this specialized mouse model is improved by the partnership between Biocytogen and Envigo to promote research applications of the triple immunodeficient B-NDG mouse. This partnership might help progress immunology research and expand the range of immunodeficient rodent model products available on the market.
(Source: Biocytogen)
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Type:
By Technology:
By Application:
By End User:
By Region:
For report customisation and delivery information contact our sales representative.
The market is anticipated to grow at a CAGR of 6.8% during the projected period.
The rat model market was valued at US$1.3 billion in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Charles River Laboratories, Envigo, genOway, Laboratory Corporation of America Holdings (LabCorp), Janvier Labs, Taconic Biosciences, Inc., TransViragen, Inc., Biomere, and Cyagen Biosciences.
The contract research organizations (CROs) segment is expected to grow at the fastest growth during the forecast period.
